Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyclASol Phase 2 in Dry Eye Disease
NCT02617667Phase 2Completed
- Sponsor
- Novaliq GmbH
- Start
- Jan 2016
- Primary completion
- Jul 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vevye in dry eye disease (DED) (4 arms), sponsored by Novaliq GmbH. Primary endpoints: Total Corneal Fluorescein Staining at 113 days and Dryness Severity Visual Analog Scale at 113 days. Started Jan 2016; status: completed.
02
Drugs
vevye
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT02617667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617667.